Fmr LLC Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

FMR LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 3.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,495,871 shares of the company's stock after purchasing an additional 199,692 shares during the period. FMR LLC owned about 13.29% of Enliven Therapeutics worth $146,157,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in ELVN. China Universal Asset Management Co. Ltd. raised its position in shares of Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock worth $233,000 after acquiring an additional 1,275 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Enliven Therapeutics by 12.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after purchasing an additional 2,944 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Enliven Therapeutics by 25.6% during the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after purchasing an additional 3,518 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $97,000. Finally, Swiss National Bank boosted its holdings in shares of Enliven Therapeutics by 13.9% in the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after buying an additional 5,100 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Transactions at Enliven Therapeutics

In related news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the sale, the chief operating officer now directly owns 323,310 shares of the company's stock, valued at $6,931,766.40. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction on Monday, January 27th. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50. Following the completion of the transaction, the chief financial officer now owns 13,000 shares in the company, valued at approximately $280,670. This trade represents a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,751 shares of company stock worth $1,178,263. Company insiders own 29.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Stock Up 2.9 %

ELVN traded up $0.46 during trading on Friday, hitting $16.53. 171,768 shares of the stock were exchanged, compared to its average volume of 266,202. The firm has a market capitalization of $810.04 million, a P/E ratio of -8.70 and a beta of 1.03. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03. The stock has a fifty day moving average price of $19.87 and a two-hundred day moving average price of $23.08.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.